The Society of Nuclear Medicine in Reston, Va., has begun a $5 million, five-year molecular imaging project called “Bench to Bedside.” The project’s goal is to bring scientific breakthroughs from the laboratory into clinical practice. The targeted technology uses imaging to examine diseases at the molecular level. GE Healthcare, Bristol-Myers Squibb Medical Imaging, Siemens Medical Solutions USA, Philips and FluoroPharma contributed to the project.